The Latest Breaking News from Lilly

Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefit

Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes and weight management. The drug demonstrated an 8% greater reduction in cardiovascular events in a key study. Mounjaro's approval strengthens Eli Lilly's position in the GLP-1 medicine market. This…

The Economic Times · Aug 28

Eli Lilly Presses Payment Processors and Social Platforms as Federal Enforcement Struggles to Slow Retatrutide Sales

With FDA enforcement stalled at the warning-letter stage, Lilly is pressuring credit card companies and social media platforms to cut off retatrutide sellers.

Medical Daily · Aug 25

An Amino Acid Dispute Between Eli Lilly and the FDA Could Delay Cheaper Retatrutide by Years

A federal court fight over whether retatrutide counts as a biologic will decide if patients wait 12 years or five for cheaper competition.

Medical Daily · Aug 25

Vanderbilt Will Build an AI Agent into Medical Records to Cut the Wait for Alzheimer's Infusions

Vanderbilt will build an AI triage agent into its EHR to speed Alzheimer's patients to treatment. What it would do, and who is funding it.

Medical Daily · Aug 7

Eczema Patients on Ebglyss Can Stretch Maintenance Shots to Every Eight Weeks, but Only After a Full Induction Course

FDA approved every-eight-week Ebglyss maintenance dosing for atopic dermatitis. Who qualifies, what maintenance dosing means, and what to ask.

Medical Daily · Aug 6

FDA Grants Breakthrough Therapy Status to a Pancreatic Cancer Drug for a Mutation Found in Roughly 1 in 50 Patients

FDA gave olomorasib breakthrough therapy status for KRAS G12C pancreatic cancer. What the designation means, who it applies to, and what it does not prove.

Medical Daily · Aug 6

Retatrutide Will Not Reach the FDA Until Early 2027, Leaving No Price and No Coverage Decision to Point To

Lilly will not file retatrutide with the FDA until early 2027. What that delay means for cost, insurance coverage, and patients considering waiting.

Medical Daily · Aug 6

Lilly Files Its GLP-1 Pill for Diabetes, and the Manufacturing Case Is Stronger Than the Access Case

Lilly submitted its oral GLP-1 for type 2 diabetes. Why pills are easier to manufacture than injectables, and why coverage still decides access.

Medical Daily · Aug 6

Lilly Says Weight Loss Drug Prices Fell 13 Percent Worldwide, but the US Decline Was Far Smaller

Lilly reported a 13% drop in realized prices, but US prices fell only 3%. Here is what that means for Zepbound patients and out-of-pocket costs.

Medical Daily · Aug 6

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.

Barchart · Aug 6